Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD

Breast

SWOG-S2007
A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases
https://www.clinicaltrials.gov/ct2/show/NCT04647916
Gayathri Nagaraj, MD

CNS

Glioma

INV INT-Differentiating Glioma (AXUMIN)- 5180227
Differentiating brain tumor recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://www.clinicaltrials.gov/ct2/show/NCT03925675
Warren Boling, MD

Glioblastoma

SWOG-NRG-BN007
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
https://www.clinicaltrials.gov/ct2/show/NCT04396860
Chien-Shing Chen, MD, PhD

COVID-19

Statera BioPharma-ST205-101-002
Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients with Mild COVID 19 Who Are at High Risk of Disease Progression
https://clinicaltrials.gov/ct2/show/NCT04708327
Jennifer Veltman, M.D.
SWOG-NRG-BN007
The COVID-19 and Cancer Consortium (CCC19) Registry
https://clinicaltrials.gov/ct2/show/NCT04354701
Gayathri Nagaraj, MD

Germ Cell

SWOG-S1823
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT04435756
Brian Hu, MD

GI

Esophageal

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Pancreas

INV INT-Pancreatic - 5170277
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma
https://www.clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

Liver

NeuWave NEU-2017-04
A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://www.clinicaltrials.gov/ct2/show/NCT04107766
Roger Tomihama, MD

Liver

Neuwave-NEU-2017-03
A Multicenter Study to Evaluate NEUWAVE Microwave Ablation System Using Ablation Confirmation in Patients with A Soft-Tissue Liver Lesion
https://www.clinicaltrials.gov/ct2/show/NCT03753789
Roger Tomihama, MD
Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases 
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD

Colon

Penn State-Colon Registry - 5180134
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Mark E. Reeves, MD, PhD

Colorectal

SWOG-S0820
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with E
https://www.clinicaltrials.gov/ct2/show/NCT1349881
Chung-Tsen Hsueh, MD, PhD

GU

Prostate

COMPPARE
Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03561220
Jerry Slater, MD

Bladder

SWOG-S1600
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMmune)
https://www.clinicaltrials.gov/ct2/show/NCT03757949
Brian Hu, MD

Bladder

UROGEN-BL011
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
https://www.clinicaltrials.gov/ct2/show/NCT05243550
Brian Hu, MD

Urothelial

QED-QGBJ398-302
The Proof 302 study of infigratinib in adjuvant urothelial carcinoma is launching soon and patients can be identified NOW
https://clinicaltrials.gov/ct2/show/NCT04197986
Brian Hu, MD

GYN

Multiple

INV INT Paclitaxel - 5180198
Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426
Linda Hong, MD

Ovarian

INV INT-Ovarian HIPEC-5150302
Investigator Initiated HIPEC Ovarian: Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098
Mazdak Momeni, MD

Ovarian/ Peritoneum

SWOG-NRG-GY019
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://www.clinicaltrials.gov/ct2/show/NCT04095364
Yevgeniya Ioffe, MD

Lung

ALLIANCE-A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD

NSCLC

ECOG-ACRIN-E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992
Hamid Mirshahidi, MD

NSCLC

ALLIANCE-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://www.clinicaltrials.gov/ct2/show/NCT04267848
Hamid Mirshahidi, MD

NSCLC

SWOG-S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
https://clinicaltrials.gov/ct2/show/NCT04214262
Hamid Mirshahidi, MD

NSCLC

SWOG-RTOG-1308
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
https://clinicaltrials.gov/ct2/show/NCT01993810
David Bush, MD

NSCLC

SWOG-LUNGMAP
A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
https://www.clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD

SCLC

SWOG-S1929
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04334941
Hamid Mirshahidi, MD

LS-SCLC

Merck-MK-7339-013-02
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04624204
Hamid Mirshahidi, MD

NSCLC

SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
Hamid Mirshahidi, MD

Melanoma

Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
Jukes Namm, MD

Multiple

SWOG-S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013
Chung-Tsen Hsueh, MD, PhD
UOP-Ostomy Telehealth
Ostomy Telehealth Self-Management Training for Cancer Survivors
https://www.clinicaltrials.gov/ct2/show/NCT03913715
Fabrizio Luca, M.D.

Registry

Radiation Medicine
Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941
Jerry Slater, MD
Penn State-Colon Registry
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Mark E. Reeves, MD, PhD

Soft Tissue Sarcoma

Radiation Medicine
A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831
Gary Yang, MD

Solid Tumors

Apollomics-APL-101-01
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03175224
Hamid Mirshahidi, MD
Amgen-20190135-A
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (proposed generic name for AMG 510) in Combination With Trametinib and in Combination With Trametinib and Panitumumab in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol A)
https://clinicaltrials.gov/ct2/show/NCT03600883
Hamid Mirshahidi, MD
Amgen-20190135-C
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation 
(CodeBreak 101 Subprotocol C)
https://clinicaltrials.gov/ct2/show/NCT04185883
Hamid Mirshahidi, MD
Amgen-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
https://clinicaltrials.gov/ct2/show/NCT04185883
Hamid Mirshahidi, MD

Transplant

PTLD

ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
Huynh Cao, MD